Publications
139
Citations
11,163
Est. group size
~12
Recurring co-author estimate
Active years
54
Publishing since 1973
Typically publishes in teams of ~15 · 12% small-team papers (≤3 authors) · across 17 venues
- Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update
Journal of Clinical Oncology · 2026
- Oral Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors: Call to Action
JCO Oncology Practice · 2025
- Pneumatosis Intestinalis Following Immune Checkpoint Inhibitor Therapy
2025
- Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events
Journal for ImmunoTherapy of Cancer · 2024
- Commentary to: Cancer and treatment specific incidence rates of immune related adverse events induced by immune checkpoint inhibitors: a systematic review
British Journal of Cancer · 2024
- Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline
Practical Radiation Oncology · 2023
- Pneumatosis intestinalis in cancer patients who received immune checkpoint inhibitors
Journal of Cancer Research and Clinical Oncology · 2023
- Confirmatory <scp><i>DPYD</i></scp> Testing in Patients Receiving Fluoropyrimidines Who are Suspected <scp><i>DPYD</i></scp> Variant Carriers Based on a Genetic Data Repository
Clinical Pharmacology & Therapeutics · 2023
- Effects of immunosuppressive treatment on patient outcomes after immune checkpoint inhibitor-related gastrointestinal toxicity
Journal of Cancer Research and Clinical Oncology · 2023
- Treatment Exposure from Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response
2023
- EOX Dose Modifications from Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response
2023
- Treatment Exposure from Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response
2023
- Supplementary Table S1 from Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
2023
- Supplementary Figure S2 from Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
2023
- Supplementary Figure S1 from Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
2023
- Journal of Clinical Oncology×31
- Journal of the National Comprehensive Cancer Network×6
- Journal of Thoracic Oncology×5
- Clinical Cancer Research×3
- Clinical Lung Cancer×3
- Hossein Borghaei
Medicine · The Ohio State University
- Angel Qin
Medicine · University of Michigan
- David P. Carbone
Medicine · The Ohio State University
- Erin M. Bertino
Medicine · The Ohio State University
- Shadia I. Jalal
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile